Efficacy and safety of cefepime

The Lancet Infectious Diseases

Volumn 9, Issue 1, 2009, Pages 4-6

  Towne, Trent G ^a   Lewis, James S ^b   Echevarria, Kelly ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY HEALTH SYSTEM   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME;

BACTERIAL INFECTION; BLEEDING; BRAIN DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EPILEPTIC STATE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LETTER; LIVER FAILURE; LUNG EMBOLISM; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 57449118695     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70288-3     Document Type: Letter

References (15)

1. Yahav D., Paul M., Fraser A., Sarid N., and Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7 (2007) 338-348
2. Kebudi R., Görgün O., Ayan I., Gürler N., Akici F., and Töreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 36 (2001) 434-441
3. Mustafa M.M., Carlson L., Tkaczewski I., McCracken Jr. G.H., and Buchanan G.R. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 20 (2001) 362-369
4. Tamura K., Matsuoka H., Tsukada J., et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + amnioglycosides: comparative study. Am J Hematol 71 (2002) 248-255
5. Cornely O.A., Bethe U., Seifert H., et al. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. Ann Hematol 81 (2002) 37-43
6. Chuang Y.Y., Hung I.J., Yang C.P., Jaing T.H., Lin T.Y., and Huang Y.C. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 21 (2002) 203-209
7. Wang F.D., Liu C.Y., Hsu H.C., et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenia patients. Chemotherapy 45 (1999) 370-409
8. Ramphal R., Haddow A., and McCracken G. A comparative study of cefepime versus ceftazidime in the treatment of adult cancer patients with fever and neutropenia. Joint clinical/statistical review of NDA 50,679/SE1-002. http://www.fda.gov/cder/foi/nda/97/050679s002_maxipime_medr_P4.pdf and http://www.fda.gov/cder/foi/nda/97/050679s002_maxipime_medr_P4.pdf (accessed Dec 2, 2008).
9. Biron P., Fuhrmann C., Cure H., et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Chemother 42 (1998) 511-518
10. Cherif H., Björkholm M., Engervall, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 36 (2004) 593-600
11. Cordonnier C., Herbrecht R., Pico J.L., et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 24 (1997) 41-51
12. Bow E.J., Rotstein C., Noskin G.A., et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43 (2006) 447-459
13. Glauser M., Dekker A.W., Van Marwijk-Kooy M., et al. A multicenter comparative study of cefepime vs ceftazidime as empiric therapy in the treatment of febrile episodes of neutropenic patients. Joint clinical/statistical review of NDA 50,679/SE1-002. http://www.fda.gov/cder/foi/nda/97/050679s002_maxipime_medr_P3.pdf (accessed Dec 2, 2008).
14. Chandrasekar P.H., and Arnow P.M. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 34 (2000) 989-995
15. FDA. Update of safety review: follow up to the November 14, 2007, communications about the ongoing safety review of cefepime (marketed as Maxipime). http://www.fda.gov/cder/drug/early_comm/cefepime_update_200805.htm (accessed Dec 2, 2008).